Dimerix Limited (ASX: DXB)

Dimerix Limited (ASX: DXB) is discovering and developing important new drug therapies for major unmet medical needs identified using a proprietary cell-based drug discovery platform. www.dimerix.com

Dimerix ASX DXB REMAP-CAP lead drug candidate Acute Respiratory Distress Syndrome ARDS COVID-19

Dimerix’s lead drug candidate to be included in key clinical study for COVID-19 respiratory patients

A lead drug candidate developed by clinical-stage biopharmaceutical company Dimerix Limited (ASX: DXB) has been selected for inclusion in a glob...
Dimerix ASX DXB DMX Therapeutic Goods Administration TGA Special Access Scheme SAS

Patients continue Dimerix’s DMX-200 treatment post-trial under TGA scheme

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) received an operational boost earlier today after announcing that patients from phas...
Dimerix ASX DXB DMX-700 Chronic Obstructive Pulmonary Disease COPD drug pipeline

Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls “an important new dis...
Dimerix ASX DXB orphan drug designation EU Europe DMX-200 kidney Dr Nina Webster

Dimerix receives orphan drug designation in Europe for DMX-200

Drug development company Dimerix (ASX: DXB) has confirmed that the European Commission (EC) has approved its DMX-200 drug to be used as an “orph...
Proteomics International Dimerix ASX PIQ DXB kidney disease

Proteomics International and Dimerix join forces to combat kidney disease

Medical technology company Proteomics International (ASX: PIQ) has teamed up with biotech stock Dimerix (ASX: DXB) to investigate the potential ...
Dimerix ASX DXB positive kidney disease trial shares rally

Dimerix shares rally on positive results from kidney disease trial

Dimerix Limited (ASX: DXB) shares have rallied over 36% as the company reported positive safety and efficacy data following its now completed 27...